

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 401/12, A61K 31/505	A1	(11) International Publication Number: WO 98/33791 (43) International Publication Date: 6 August 1998 (06.08.98)
(21) International Application Number: PCT/US98/01429 (22) International Filing Date: 26 January 1998 (26.01.98) (30) Priority Data: 60/037,183 4 February 1997 (04.02.97) US 60/050,893 26 June 1997 (26.06.97) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; 5 Research Parkway, Wallingford, CT 06492-7660 (US). (72) Inventors: BRUCE, Marc, A.; 76 Tankwood Road, Walling- ford, CT 06492 (US). POINDEXTER, Graham, S.; 15 Fox Hollow Road, Old Saybrook, CT 06475 (US). JOHNSON, Graham; 57 Bridle Path Lane, Madison, CT 06443 (US). (74) Agent: ALGIERI, Aldo, A.; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: DIHYDROPYRIMIDONE DERIVATIVES AS NPY ANTAGONISTS (57) Abstract <p>The present invention provides a series of non-peptidergic antagonists of NPY comprising piperidine derivatives of 4-phenyl-1,4-dihydropyrimidinones of formula (I), wherein R, R¹ and R² are defined herein. As antagonists of NPY-induced feeding behavior, these compounds are expected to act as effective anorexiants agents in promoting weight loss and treating eating disorders.</p> <div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakistan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DIHYDROPYRIMIDONE DERIVATIVES**AS NPY ANTAGONISTS**

5

10

Field of the Invention

The present invention provides novel heterocyclic carbon compounds comprising 4-phenyl-1,4-dihydropyrimidinones with a piperidinyI containing moiety attached to the 3-position of the 4-phenyl ring. These compounds act as NPY antagonists.

15

Background of the Invention

20 Neuropeptide Y (NPY) is a 36 amino acid peptide first isolated in 1982 from porcine brain [K. Takemoto, Proc. Nat. Acad. Sci., (1982) 79, 5485-5489; D.R. Gehlert, Life Sciences, (1994) 55, 551-62; L. Grundemar and R. Hakanson, TIPS, (1994) 15, 153-159; J. M. Lundberg, TIPS, (1996) 17, 301-304; C. Wahlestedt and D.J. Reis, Ann. Rev.
25 Pharmacol. Toxicol., (1993) 32, 309-352; P.A. Hipskind, Ann. Rep. Med. Chem., (1996), 31, 1-10; J.D. White, Regulatory Peptides, (1993) 49, 93-107; A. Sahu and S.P. Kalra, Trends Endocrinol. Metab., (1993) 4, 217-224; Y. Dumont, J.-C. Martel, A. Fournier, S. St. Pierre and R. Quirion, Prog. Neurobiol., (1992) 38, 125-167; M.C. Michel and A. Buscher,
30 Drugs of the Future, (1992) 17, 39-45; M.C. Michel, TIPS, (1991) 12, 389-394; J. Lehmann, Drug. Dev. Res., (1990) 19, 329-351; G. Williams, Peptides, (1995) 4, 757-771]. The peptide is a member of a larger peptide family which also includes peptide YY (PYY), pancreatic peptide (PP), and the non-mammalian fish pancreatic peptide Y (PY).

- 2 -

Neuropeptide Y is very highly conserved in a variety of animal, reptile and fish species. It is found in many central and peripheral sympathetic neurons and is the most abundant peptide observed in the mammalian brain. In the brain, NPY is found most abundantly in limbic regions. The peptide has been found to elicit a number of physiological responses including appetite stimulation, anxiolysis, hypertension, and the regulation of coronary tone.

Structure-activity studies with a variety of peptide analogs (fragments, alanine replacements, point mutations, and internal deletion/cyclized derivatives) suggest a number of receptor subtypes exist for NPY [L. Grundemar and R. Hakanson, TIPS, (1994) 15, 153-159]. These currently include the Y₁, Y_{1-like}, Y₂, Y₃, and the Y₄ subtypes.


Although specific peptidic antagonists have been identified for most of the subtypes, few selective non-peptidic antagonists have been reported to date. Several competitive but non-selective, non-peptidic antagonists are known. The heterocyclic guanidine derivative He 90481 (4) was found to be a weak but competitive antagonist of NPY-induced Ca⁺⁺ entry in HEL cells (pA₂=4.43) [M.C. Michel and H.J. Motulsky, Annu. Rev. N.Y. Acad. Sci., (1990) 611, 392-394; U.S. Patent 4,912,119, 1990 (Heumann Pharma GMBH)]. The compound was also found to have α_2 -adrenergic and histaminergic activity at this dose range. D-Myo-inositol-1,2,6-triphosphate (5) was reported to be a potent but non-competitive antagonist to NPY-induced contractions in guinea pig basilar artery [L. Edvinsson, M. Adamsson and I. Jansen, Neuropeptides, (1990) 17, 99-105]. Similarly, the benextramine-like bisguanidines 6a and 6b were reported to displace ³H-NPY in rat brain (IC₅₀, 19 and 18.4 μ M) and to display functional antagonism in rat femoral artery [M.B. Doughty, C. Chaurasia and K. Li, J. Med. Chem., (1993) 36, 272-79; M.B. Doughty, S.S. Chu, G.A. Misse and R. Tessel, BioMed. Chem. Lett., (1992) 2,

- 3 -

1497-1502; C. Chaurasia, G. Misse, R. Tessel and M.B. Doughty, J. Med. Chem., (1994) 37, 2242-48]. The bisguanidine 6b was shown to be functionally selective for the Y_2 receptor since it antagonized the effect of the NPY_2 agonist NPY_{13-36} but had no effect on the vasoconstrictive activity of the NPY_1 agonist [Leu³¹, Pro³⁴] NPY [C. Chaurasia, G. Misse, R. Tessel and M.B. Doughty, J. Med. Chem., (1994) 37, 2242-48].

A substantial body of art has accumulated over the past two decades with respect to 4-aryl-1,4-dihydropyridine compounds. A large number of these possess calcium antagonist properties and find utility in the treatment of cardiovascular diseases. Several 4-aryl-1,4-dihydropyridines with piperidine-ring-containing-substituents have been reported.

A series of compounds of formula (1) was claimed to be




(1)

useful as vasodilators, antihypertensives and diuretics in U.S. 4,707,486.

20


A series of dihydropyridines, including compounds of formula (2), were disclosed and claimed to have antitumor promoting activity in European Patent Application 533,504.



(2)

25


European Patent Application 534,520 discloses related compounds having formula (3) wherein R₅ is alkyl, phenyl and aralkyl.



(3)

5


A compound of formula (4) has been disclosed in JO 4049-237-A and claimed to be an inhibitor of Phospholipase A₂.



(4)

10

Of less significance is a series of antihypertensive dihydropyridine anilide derivatives disclosed in U.S. 4,829,076 and containing compounds of formula (5)




(5)

15


in which B is a chemical bond or an alkylene group.

Dipeptide-like sulfonamidoyl amidine derivatives of formula (6)




- 5 have been disclosed as selective NPY Y_1 antagonists. See: French Patent 9,301,686; Serradeil-LeGal, et al., Society for Neuroscience, (1994) abstract no. 376.14.

A guanidine derivative of formula (7) having NPY Y_1 selective
10 receptor antagonist activity was



disclosed by Rudolf, et al., Eur. J. Pharmacology, (1994) 271, R11-13.

A series of substituted benzylamine derivatives of the general formula (8) having NPY Y₁ receptor antagonist activity



(8)

5


was disclosed by Peterson, et al. in International Patent Application WO 96/14307, published May 17, 1996.

These reference compounds are readily distinguished structurally from the compounds of the instant invention by virtue of many of the art compounds having the piperidine substituents attached to the dihydropyridine ring itself as well as by the nature of most of the linking functional groups, e.g. oxyalkylenyl and carboxylate groups. In contrast, compounds of the instant invention contain an alkylenylpiperidine moiety attached to the 3-position of the 4-phenyl ring by means of an urea connection. Not only are the present compounds structurally novel, they also have been discovered to possess novel NPY antagonist activity.

In summary, the prior art does not disclose nor suggest the unique combination of structural fragments which embody these novel dihydropyrimidinone derivatives as having good antagonist activity at NPY Y₁ receptor sites.

Summary and Detailed Description of the Invention

The present invention comprises the compounds of Formula I,



5

The term "C₁₋₃ alkyl" indicates that the alkyl group contains from one to three carbon atoms, such as methyl, ethyl, propyl and isopropyl. Preferred compounds of the instant invention are Formula I compounds wherein R is -CO₂R¹ and R¹ is methyl. Most preferred compounds are those wherein R² is selected from substituted phenyl, particularly with methoxy substituents.

10

The compounds of the present invention can exist as optical isomers and both the racemic mixtures of these isomers as well as the individual optical isomers themselves are within the scope of the present invention. The racemic mixtures can be separated into their individual isomers through well known techniques such as the separation of the diastereomeric salts formed with optically active acids, followed by conversion back to the optically active bases.

15

20


As indicated, the present invention also pertains to the pharmaceutically acceptable non-toxic salts of these basic compounds. Such salts include those derived from organic and inorganic acids such as, without limitation, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, dichloroacetic acid,

25

tartaric acid, lactic acid, succinic acid, citric acid, maleic acid, fumaric acid, sorbic acid, aconitic acid, salicylic acid, phthalic acid, enanthic acid, and the like.

- 5 The Formula I compounds can also be quaternized by standard techniques to yield quaternary piperidinium salt products of Formula I. Quaternization would be expected to maximize the peripheral effects of Formula I compounds and minimize brain penetration.
- 10 The compounds of the present invention may be prepared by various procedures such as those illustrated herein in the examples, in the reaction schemes and variations thereof which would be evident to those skilled in the art. The various compounds of Formula I may advantageously be prepared from the dihydropyrimidinone
- 15 intermediates Va, Vb and Vc as illustrated in Reaction Schemes 2 and 3.

The various dihydropyrimidinone intermediates are generally prepared from the Knoevenagel adduct of Formula II as illustrated in Reaction Scheme 1.

SCHEME 1

5


It will be appreciated by those skilled in the art that the reaction of the intermediate of Formula II with O-methylisourea produced a mixture of methoxypyrimidine isomers of Formulas III and IV. Advantageously, the methoxypyrimidine isomer of Formula III may selectively be crystallized from the mixture of isomers by the method described herein. The resulting filtrate that contains a residual mixture of isomers of Formulas III and IV may readily be hydrolyzed under acidic conditions in aqueous tetrahydrofuran to provide the 2-oxopyrimidine intermediate of Formula Va.


15

The intermediates of Formulas Vb and Vc are advantageously prepared from the single methoxypyrimidine compound of Formula III by alkylation and acylation reactions, respectively. The alkylation of the

compound of Formula III with a lower alkyl alkylating agent such as methyl iodide in an inert organic solvent followed by acid hydrolysis of the methoxy group afforded the intermediate of Formula Vb. The acylation of the compound of Formula III with a lower alkyl ester of chloroformate in the presence of about one equivalent of a base such as pyridine, lutidine, triethylamine and the like in an inert organic solvent then followed by acid hydrolysis of the methoxy group afforded the intermediate of Formula Vc.

10 The compounds of Formula I were prepared from the intermediates of Formulas Va, Vb and Vc as outlined by the process in Reaction Scheme 2 or the alternate process as outlined in Scheme 3. In Reaction Scheme 2, the nitrophenyl intermediates of Formulas Va, Vb and Vc were subjected to catalytic hydrogenation in an acetic acid
15 solvent to produce the aminophenyl intermediates of Formulas VIa, VIb and VIc which were then coupled with the activated carboxylate intermediate of Formula VII to produce the corresponding dihydropyrimidinone compounds of Formula Ia, Ib and Ic. It should be understood that the intermediate of Formula VII can readily be prepared
20 by methods described in the literature and preferably by the method described herein.

SCHEME 2

SCHEME 3

5

In an alternate process, the preparation of the dihydropyrimidinone compound of Formula Id is illustrated in Reaction Scheme 3. An aminophenyl compound of Formula VIc is first treated with 3-chloropropyl isocyanate to produce a urea intermediate of Formula VIII which is then used to alkylate 4-(3-methoxyphenyl)-piperidine with sodium iodide as catalyst under basic conditions in an inert solvent to afford the compound of Formula Id.

Additional reactions intermediates and Formula I products can be prepared by appropriate modification of the foregoing synthetic schemes and procedures. Such modifications would be obvious to those skilled in the art.

The compounds of this invention demonstrate binding affinity at NPY Y₁ receptors. This pharmacologic activity is assayed in SK-N-MC (human neuroblastoma) cell membranes using iodine-125-labeled I-PYY as a radioligand. The compounds of this invention had good binding affinities as evidenced by IC₅₀ values being about 1 μM or less at NPY Y₁ receptors. Preferred compounds have IC₅₀ values less than 100 nM.

Although as a class, these types of compounds have significant affinity for α₁-adrenergic receptors and/or Ca⁺⁺ channels, the compounds of this invention possess much weaker affinities for α₁ adrenergic receptors and Ca⁺⁺ channels. Pharmacologically, these compounds act as selective NPY antagonists at NPY Y₁ receptor sites. As such, the compounds of Formula (I) are of value in the treatment of a wide variety of clinical conditions which are characterized by the presence of an excess of neuropeptide Y. Thus, the invention provides methods for the treatment or prevention of a physiological disorder associated with an excess of neuropeptide Y, which method comprises administering to a mammal in need of said treatment an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof. The term "physiological disorder associated with an excess of neuropeptide Y" encompasses those disorders associated with an inappropriate stimulation of neuropeptide Y receptors, regardless of the actual amount of neuropeptide Y present in the locale.

These physiological disorders include:

- disorders or diseases pertaining to the heart, blood vessels or the renal system, such as vasospasm, heart failure, shock, cardiac hypertrophy, increased blood pressure, angina, myocardial infarction,

sudden cardiac death, congestive heart failure, arrhythmia, peripheral vascular disease, and abnormal renal conditions such as impaired flow of fluid, abnormal mass transport, or renal failure;

- conditions related to increased sympathetic nerve activity for example, during or after coronary artery surgery, and operations and surgery in the gastrointestinal track;

- cerebral diseases and diseases related to the central nervous system, such as cerebral infarction, neurodegeneration, epilepsy, stroke, and conditions related to stroke, cerebral vasospasm and hemorrhage, depression, anxiety, schizophrenia, dementia, seizure, and epilepsy;

- conditions related to pain or nociception;

- diseases related to abnormal gastrointestinal motility and secretion, such as different forms of ileus, urinary incontinence, and Crohn's disease;

- abnormal drink and food intake disorders, such as obesity, anorexia, bulimia, and metabolic disorders;

- diseases related to sexual dysfunction and disorders, such as male erectile dysfunction and benign prostatic hyperplasia, and reproductive disorders;

- conditions or disorders associated with inflammation;

- respiratory diseases, such as asthma and conditions related to asthma and bronchoconstriction;

- diseases related to abnormal hormone release, such as leutinizing hormone, growth hormone, insulin and prolactin;

- sleep disturbance and diabetes.

There is evidence that NPY contributes to certain symptoms in these disorders: hypertension, eating disorders, and depression/anxiety [C.

- 5 Wahlestedt and D.J. Reis, Annual Rev. Pharmacol. Toxicol., (1993) 32, 309-52; p. 331]; as well as circadian rhythms. Compounds of this invention are expected to be useful in treating these disorders as well as sleep disturbance and diabetes.

- 10 These compounds are expected to block NPY-induced feeding in test animals by intraperitoneal administration to the animal prior to inducing feeding behavior with NPY. Taken together, these tests indicate that the compounds of this invention would be useful anorexiant and would function as anti-obesity agents with further use in
15 various clinical eating disorders. Thus, another aspect of the invention concerns a process for reducing food intake in an obese mammal or a mammal with an eating disorder. The process comprises systemic administration to such a mammal of an anorexiant-effective dose of a Formula I compound or a pharmaceutically acceptable acid addition salt
20 and/or hydrate thereof.

- On the basis of pharmacologic testing, an effective dose given parenterally could be expected to be in a range of about 0.05 to 1 mg/kg body weight and if given orally would be expected to be in the range of
25 about 1 to 20 mg/kg body weight.

- For clinical applications, however, the dosage and dosage regimen must in each case be carefully adjusted, utilizing sound professional judgment and considering the age, weight and condition of
30 the recipient, the route of administration and the nature and gravity of the illness. Generally, the compounds of the instant invention will be administered in the same manner as for available anorexiant drugs such

as Diethylpropion, Mazindol, or Phentermine and the daily oral dose would comprise from about 70 to about 1400 mg, preferably 500 to 1000 mg administered from 1 to 3 times a day. In some instances, a sufficient therapeutic effect can be obtained at lower doses while in others, larger
5 doses will be required.

The term systemic administration as used herein refers to oral, buccal, transdermal, rectal, and parenteral (i.e. intramuscular, intravenous, and subcutaneous) routes. Generally, it will be found that
10 when a compound of the present invention is administered orally, which is the preferred route, a larger quantity of reactive agent is required to produce the same effect as a smaller quantity given parenterally. In accordance with good clinical practice, it is preferred to administer the instant compounds at a concentration level that will produce effective
15 anorectic effects without causing any harmful or untoward side effects. Similarly, the instant compounds can be administered to treat hypertension, depression, diabetes and anxiety disorders.

Therapeutically, the instant compounds are generally given as
20 pharmaceutical compositions comprised of an effective anorectic amount of a compound of Formula I or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier. Pharmaceutical compositions for effecting such treatment will contain a major or minor amount, e.g. from 95 to 0.5% of at least one compound of
25 the present invention in combination with the pharmaceutical carrier, the carrier comprising one or more solid, semi-solid, or liquid diluent, filler, and formulation adjuvant which is non-toxic, inert and pharmaceutically acceptable. Such pharmaceutical compositions are preferably in dosage unit forms; i.e., physically discrete units containing a
30 predetermined amount of the drug corresponding to a fraction or multiple of the dose which is calculated to produce the desired therapeutic response. The dosage units can contain 1, 2, 3, 4, or more single doses,

or, alternatively, one-half, one-third, or one-fourth of a single dose. A single dose preferably contains an amount sufficient to produce the desired therapeutic effect upon administration at one application of one or more dosage units according to the pre-determined dosage regimen

5 usually a whole, half, third, or quarter of the daily dosage administered once, twice, three, or four times a day. Other therapeutic agents can also be present. Pharmaceutical compositions which provide from about 50 to 1000 mg of the active ingredient per unit dose are preferred and are conventionally prepared as tablets, lozenges, capsules, powders,

10 transdermal patches, aqueous or oily suspensions, syrups, elixirs, and aqueous solutions. Preferred oral compositions are in the form of tablets or capsules and may contain conventional excipients such as binding agents (e.g. syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone), fillers (e.g. lactose, sugar, maize-starch, calcium

15 phosphate, sorbitol, or glycine), lubricants (e.g. magnesium stearate, talc, polyethylene glycol or silica), disintegrants (e.g. starch) and wetting agents (e.g. sodium lauryl sulfate). Solutions or suspensions of a Formula I compound with conventional pharmaceutical vehicles are generally employed for parenteral compositions such as an aqueous

20 solution for intravenous injection or an oily suspension for intramuscular injection. Such compositions having the desired clarity, stability and adaptability for parenteral use are obtained by dissolving from 0.1% to 10% by weight of the active compound in water or a vehicle consisting of a polyhydric aliphatic alcohol such as glycerine, propyleneglycol, and

25 polyethelene glycols or mixtures thereof. The polyethyleneglycols consist of a mixture of non-volatile, usually liquid, polyethyleneglycols which are soluble in both water and organic liquids and which have molecular weights from about 200 to 1500.

Description of the Specific Embodiments

The compounds which constitute this invention and their methods of preparation will appear more fully from a consideration of the following
5 examples which are given for the purpose of illustration only and are not to be construed as limiting the invention in sphere or scope. All temperatures are understood to be in degrees C when not specified.

The nuclear magnetic resonance (NMR) spectral characteristics
10 refer to chemical shifts (δ) expressed in parts per million (ppm) versus tetramethylsilane (TMS) as reference standard. The relative area reported for the various shifts in the proton NMR spectral data corresponds to the number of hydrogen atoms of a particular functional type in the molecule. The nature of the shifts as to multiplicity is reported
15 as broad singlet (br s), singlet (s), multiplet (m), doublet (d), triplet (t) doublet of doublets (dd), quartet (q) or pentuplet (p). Abbreviations employed are DMSO- d_6 , (deuterodimethylsulfoxide), $CDCl_3$ (deuteriochloroform), and are otherwise conventional. The infrared (IR) spectral descriptions include only absorption wave numbers (cm^{-1})
20 having functional group identification value. The IR determinations were generally employed using potassium bromide (KBr) as diluent. The elemental analyses are reported as percent by weight.

General Method for the Preparation of Intermediate VII

25

STEP A. 3-(4-Phenyl-1-piperidiny)propanenitrile

A mixture of 4-phenylpiperidine (23.5 g, 146 mmol) and acrylonitrile (12.0 mL, 180 mmol) in MeCN (150 mL) was refluxed for 4 h,
30 and then the solvent removed in vacuo. The residue was partitioned between CH_2Cl_2 (200 mL) and H_2O (100 mL), the organic extract was

dried over Na₂SO₄, and the solvent removed in vacuo to yield an amber oil (32.7 g, quantitative yield): ¹H NMR (DMSO-d₆) δ 7.25 (m, 5 H), 2.96 (d, 2 H, J = 11.4 Hz), 2.67 (t, 2 H, J = 7.5 Hz), 2.58 (t, 2 H, J = 7.5 Hz), 2.48 (m, 1 H), 2.06 (t, 2 H, J = 12.0 Hz), 1.70 (m, 2 H), 1.64 (t, 2 H, J = 12.0 Hz); ¹³C NMR (DMSO-d₆) δ 146.1, 128.3, 126.7, 126.0, 120.1, 53.2, 41.7, 33.0, 15.1.

Anal. Calcd for C₁₄H₁₈N₂ • 0.2 H₂O: C, 77.17; H, 8.51; N, 12.86.

Found: C, 77.13; H, 7.95; N, 12.65

10

STEP B. 1-(3-Aminopropyl)-4-phenylpiperidine

A solution of the compound of Step A (31 g, 140 mmol) in MeOH (170 mL) and 30% aqueous NH₃ (30 mL) containing Raney nickel was shaken in a Parr apparatus under H₂ (50 psi) for 1 h. The catalyst was then removed by filtration over Celite, and the solvent removed in vacuo to yield a light yellow paste (31.5 g, quantitative yield) [Wade, P. C.; and Vogt, R., US Patent No. 3,995,045, 1976].

20 **STEP C. 1-[[[3-(4-Phenyl-1-piperidiny)propyl]amino]-carbonyl]imidazole (VII)**

To a stirred solution of 1,1'-carbonyldiimidazole (CDI, 15 g, 92 mmol) in MeCN (200 mL) at 0 °C under N₂ was added dropwise a solution of the compound of Step B (10 g, 46 mmol) in CH₂Cl₂ (100 mL) over 30 min. The resulting mixture was stirred an additional 30 min at 0 °C, then for 30 min at room temperature. The reaction was quenched with H₂O (100 mL), and the resulting mixture was extracted with ether (200 mL). The organic extract was washed with H₂O (2 X 100 mL), followed by brine (100 mL), and dried over Na₂SO₄. The solvent was removed in vacuo to afford a light amber oil of the intermediate of

30

Formula VII (12.3 g, 85% yield): ^1H NMR (CDCl_3) δ 8.90 (s, 1 H), 8.18 (s, 1 H), 7.41 (s, 1 H), 7.31 (m, 2 H), 7.21 (m, 3 H), 7.10 (s, 1 H), 3.54 (m, 2 H), 3.14 (d, 2 H, $J = 11.7$ Hz), 2.60 (t, 2 H, $J = 5.4$ Hz), 2.07 (t, 2 H, $J = 12.0$ Hz), 1.08 (m, 6 H); ^{13}C NMR (CDCl_3) δ 149.0, 145.5, 136.2, 130.4, 128.6, 126.7, 126.4, 115.8, 59.1, 54.6, 42.4, 33.4, 23.5.

Anal. Calcd for $\text{C}_{18}\text{H}_{24}\text{N}_4\text{O} \cdot 0.9 \text{H}_2\text{O}$: C, 65.79; H, 7.91; N, 17.05.

Found: C, 66.13; H, 7.62; N, 16.83.

10

EXAMPLE 1

1,2,3,4-Tetrahydro-6-methyl-4-(3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, methyl ester

15

Following the general method described by O'Reilly, B. C.; and Atwal, K. S. Heterocycles, (1987) 26, 1185, a mixture of the compound of Formula II [prepared by the method described by Jones, G. Org. Reactions, (1967) 15, 204] (20 g, 80 mmol), O-methylisourea $\cdot \text{H}_2\text{SO}_4$ (17.2 g, 100 mmol) and NaHCO_3 (25 g, 300 mmol) in DMF (200 mL) was stirred at room temperature for 1 h, and then heated overnight at 65 °C. The mixture was cooled, and then partitioned between EtOAc (2 X 400 mL) and H_2O (400 mL). The organic extracts were combined and rinsed with H_2O (2 X 200 mL), followed by brine (200 mL), and the solvent was removed in vacuo. The identities of the resulting methoxypyrimidine isomers were determined by ^1H NMR. A white solid (2.67 g, compound III) was isolated from Et_2O containing a small amount of MeOH. Upon standing, the mother liquor produced a second crop of white solid (2.68 g, compound IV). Subsequent crops (4.05 g) contained a mixture of compound III and IV, for a combined yield of 59%. Due to the apparent instability of the methoxypyrimidines, full characterization was not

30

obtained, and these compounds were used promptly in subsequent reactions.

A mixture of compound III and IV (5.0 g, 16 mmol) in MeOH:THF
5 1:1 (100 mL) and 3N HCl (30 mL) was stirred overnight, resulting in the
formation of a white precipitate. The solvent was removed in vacuo, and
the residue triturated in 100% EtOH to produce the title compound Va as
a white solid (3.42 g, 72% yield): mp 268-269 °C; ¹H NMR (DMSO-d₆) δ
9.40 (s, 1 H), 8.13 (d, 1 H, J = 7.5 Hz), 8.08 (s, 1 H), 7.93 (s, 1 H), 7.66 (m,
10 2 H), 5.29 (d, 1 H, J = 3.3 Hz), 3.53 (s, 3 H), 2.27 (s, 3 H); ¹³C NMR
(DMSO-d₆) δ 165.6, 151.8, 149.7, 147.9, 146.8, 132.9, 130.3, 122.4,
120.9, 98.1, 53.4, 50.9, 17.9.

Anal. Calcd for C₁₃H₁₃N₃O₅ • 0.2 H₂O • 0.1 C₂H₆O: C, 52.94; H, 4.71;
15 N, 14.03. Found: C, 53.03; H, 4.64; N, 13.73.

EXAMPLE 2

20 4-(3-Aminophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-5-pyrimidinecarboxylic acid, methyl ester

A solution of the compound of Example I in AcOH containing 10%
Pd/C and was shaken in a Parr apparatus under H₂ (50 psi) for about 1 h.
25 The catalyst was removed by filtration over Celite and the solvent was
removed in vacuo to afford the title compound as a light yellow solid
(98% yield): mp 222-234 °C; ¹H NMR (DMSO-d₆) δ 9.12 (s, 1 H), 7.63 (s,
1 H), 6.92 (t, 1 H, J = 7.5 Hz), 6.40 (m, 3 H), 5.04 (s, 2 H), 4.98 (d, 1 H, J =
3.3 Hz), 3.52 (s, 3 H), 2.22 (s, 3 H); ¹³C NMR (DMSO-d₆) δ 166.0, 152.2,
30 148.7, 148.1, 145.3, 128.8, 113.8, 112.9, 111.6, 99.2, 54.0, 50.7, 17.8.

Anal. Calcd for $C_{13}H_{15}N_3O_3 \cdot 0.25 H_2O$: C, 58.75; H, 5.89; N, 15.81.

Found: C, 59.12; H, 5.76; N, 15.39.

5

EXAMPLE 3

1,2,3,4-Tetrahydro-6-methyl-2-oxo-4-[3-[[[3-(4-phenyl-1-piperidinyl)propyl]amino]carbonyl]amino]phenyl]-5-pyrimidinecarboxylic acid, methyl ester hydrochloride

10

A mixture of the compound of Example 2 and the intermediate of Formula VII in MeCN was refluxed overnight. After the solvent was removed in vacuo from the reaction mixture, the residue was partitioned between 1N HCl (50 mL) and CH_2Cl_2 :MeOH 3:1 (6 X 50 ML). The organic extracts were combined, made basic with saturated Na_2CO_3 , dried over Na_2SO_4 , and the solvent was removed in vacuo. Flash chromatography (SiO_2 : MeOH/ CH_2Cl_2) yielded a residue of 700 mg, which was dissolved in MeOH and combined with 1N HCl/ Et_2O (1.5 mL). The solvent was removed in vacuo, and the residue triturated in acetone to afford the title compound as a pale yellow solid (455 mg, 12% yield): mp 170-178 °C (with decomposition); 1H NMR ($DMSO-d_6$) δ 10.44 (br s, 1 H), 9.19 (s, 1 H), 8.93 (s, 1 H), 7.72 (s, 1 H), 7.32 (m, 3 H), 7.22 (m, 4 H), 7.14 (t, 1 H, $J = 7.8$ Hz), 6.77 (d, 1 H, $J = 7.5$ Hz), 6.57 (t, 1 H, $J = 5.7$ Hz), 5.07 (d, 1 H, $J = 3.3$ Hz), 3.55 (m, 2 H), 3.53 (s, 3 H), 3.16 (m, 2 H), 3.00 (m, 4 H), 2.80 (m, 1 H), 2.23 (s, 3 H), 2.05 (m, 2 H), 1.93 (m, 4 H); ^{13}C NMR ($DMSO-d_6$) δ 165.9, 155.5, 152.1, 148.5, 145.2, 144.3, 140.6, 128.7, 128.6, 126.6, 119.0, 116.6, 115.5, 99.0, 54.0, 52.0, 50.8, 36.5, 25.2, 24.5, 17.9.

Anal. Calcd for $C_{28}H_{35}N_5O_4 \cdot HCl \cdot H_2O$: C, 60.05; H, 6.84; N, 12.50.
Found: C, 60.24; H, 6.57; N, 12.22.

30

EXAMPLE 4**1,2,3,6-Tetrahydro-1,4-dimethyl-6-(3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, methyl ester**

5

To a stirred solution containing the compound of Formula III obtained from the procedure of Example 1 (7.0 g, 23 mmol) in DMF (50 mL) was added NaH (60% mineral oil dispersion, 1.0 g, 25 mmol), followed by Mel (1.6 mL, 25 mmol). This mixture was stirred 30 min, and
10 then partitioned between H₂O (200 mL) and EtOAc (3 X 100 mL). The organic extracts were combined, washed with H₂O (2 X 100 mL), followed by brine (100 mL), and the solvent was removed in vacuo. The resulting 1:1 mixture of 1,6- and 1,4-dihydro-2-methoxypyrimidines was separated by flash chromatography (SiO₂: MeOH/CH₂Cl₂/Hexane), and
15 the identity of these isomers was confirmed by ¹H NMR after hydrolysis of the methoxy group. Acidic hydrolysis of the 1,6-dihydro isomer (2.42 g, 33% yield) as described for the compound of Example I afforded the title compound as a white solid (2.13 g, 92% yield): mp 217-219 °C; ¹H NMR (DMSO-d₆) δ 9.59 (s, 1 H), 8.15 (d, 1 H, J = 7.8 Hz), 8.09 (s, 1 H),
20 7.71 (m, 2 H), 5.39 (s, 1 H), 3.53 (s, 3 H), 2.72 (s, 3 H), 2.24 (s, 3 H); ¹³C NMR (DMSO-d₆) δ 165.3, 151.5, 148.8, 147.9, 144.1, 133.4, 130.4, 122.8, 121.3, 98.7, 60.5, 50.9, 32.3, 17.7.

Anal. Calcd for C₁₄H₁₅N₃O₅ • 0.1 H₂O: C, 54.76; H, 4.99; N, 13.68.

25 Found: C, 54.62; H, 4.88; N, 13.65.

EXAMPLE 5**6-(3-Aminophenyl)-1,2,3,6-tetrahydro-1,4-dimethyl-2-oxo-5-pyrimidinecarboxylic acid, methyl ester**

5

The title compound was prepared from the compound of Example 4 by the method described in Example 2, using AcOH as solvent. A white solid was obtained in quantitative yield: mp 205-209 °C; ¹H NMR (CDCl₃): δ 8.69 (s, 1 H), 7.05 (t, 1 H, J = 7.8 Hz), 6.69 (d, 1 H, J = 7.8 Hz), 6.63 (s, 1 H), 6.56 (d, 1 H, J = 7.8 Hz), 5.10 (s, 1 H), 3.63 (s, 3 H), 2.84 (s, 3 H), 2.30 (s, 3 H); ¹³C NMR (CDCl₃): δ 166.2, 153.2, 146.7, 146.6, 142.5, 129.4, 117.5, 114.8, 113.4, 100.9, 62.3, 51.0, 32.8, 18.6.

Anal. Calcd for C₁₄H₁₇N₃O₃ • 0.2 H₂O: C, 60.29; H, 6.29; N, 15.07.
Found: C, 60.56; H, 6.08; N, 14.81.

EXAMPLE 6**1,2,3,6-Tetrahydro-1,4-dimethyl-2-oxo-6-[3-[[[3-(4-phenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-5-pyrimidinecarboxylic acid, methyl ester maleate**

The title compound was prepared from the compound of Example 5 and the intermediate of Formula VII by the method described in Example 3. The solvent was removed in vacuo from the reaction mixture, and the residue partitioned between CH₂Cl₂ and H₂O. The organic extract was dried over Na₂SO₄, the solvent removed in vacuo, and the residue subjected to flash chromatography (SiO₂: MeOH/CH₂Cl₂). The resulting material was dissolved in a solution of maleic acid in CH₂Cl₂ to afford the maleate salt as a white solid (15% yield): mp 73-79 °C; ¹H NMR (DMSO-d₆) δ 9.39 (s, 1 H), 8.69 (s, 1 H),

7.24 (m, 8 H), 6.79 (d, 1 H, $J = 7.8$ Hz), 6.32 (t, 1 H, $J = 5.7$ Hz), 6.06 (s, 2 H), 5.10 (s, 1 H), 3.60 (m, 2 H), 3.53 (s, 3 H), 3.28 (br m, 2 H), 3.16 (m, 4 H), 2.82 (m, 1 H), 2.69 (s, 3 H), 2.21 (s, 3 H), 2.03 (m, 2 H), 1.86 (m, 4 H); ^{13}C NMR (DMSO- d_6) δ 167.2, 165.6, 155.5, 151.7, 147.7, 144.0, 142.2, 140.7, 135.5, 128.8, 128.6, 126.7, 126.5, 119.7, 117.2, 115.9, 99.3, 61.3, 54.1, 52.2, 50.8, 36.5, 32.3, 30.1, 24.9, 17.7.

Anal. Calcd for $\text{C}_{29}\text{H}_{37}\text{N}_5\text{O}_4 \cdot 1.25 \text{C}_4\text{H}_4\text{O}_4 \cdot \text{H}_2\text{O}$: C, 59.81; H, 6.50; N, 10.26. Found: C, 60.12; H, 6.42; N, 10.00.

10

EXAMPLE 7

1,2,3,6-Tetrahydro-4-methyl-6-(3-nitrophenyl)-2-oxo-1,5-pyrimidinedicarboxylic acid, dimethyl ester

15

The general method described by Atwal, K. S., *et al.*, J. Org. Chem., (1989) 54, 5898-907, was utilized. A solution of methyl chloroformate (0.26 mL, 4.9 mmol) in CH_2Cl_2 (5 mL) was added dropwise to a stirred solution containing the compound of Formula III (1.4 g, 4.7 mmol) and pyridine (0.4 mL, 5 mmol) in CH_2Cl_2 (15 mL) at 0°C . The resulting mixture was stirred at room temperature for 30 min, and the solvent removed in vacuo. The residue was partitioned between EtOAc and saturated Na_2CO_3 , then the organic extract was rinsed with water, followed by brine, and the solvent removed in vacuo. A mixture of the desired 1,6-dihydro-2-methoxypyrimidine and the hydrolysis product of the 1,4-isomer precipitated after addition of Et_2O . After filtration, hexane was added to the mother liquor, and the 1,6-dihydro-2-methoxypyrimidine was isolated as a white solid (1.06 g, 62% yield). Subsequent acidic hydrolysis of the methoxy group as described for the compound of Example 1 afforded the title compound as a white solid (690 mg, 90% yield): mp $152\text{--}155^\circ\text{C}$; ^1H NMR (DMSO- d_6) δ 10.32 (s,

20

25

30

- 26 -

1 H), 8.17 (m, 1 H), 8.04 (s, 1 H), 7.71 (m, 2 H), 6.23 (s, 1 H), 3.78 (s, 3 H), 3.66 (s, 3 H), 2.30 (s, 3 H); ^{13}C NMR (DMSO- d_6) δ 165.0, 153.7, 148.6, 148.3, 148.0, 142.1, 132.8, 130.6, 123.2, 120.7, 102.2, 54.8, 54.3, 51.6, 17.3.

5

Anal. Calcd for $\text{C}_{15}\text{H}_{15}\text{N}_3\text{O}_7$: C, 51.58; H, 4.33; N, 12.03.

Found: C, 51.49; H, 4.15; N, 12.07.

10

EXAMPLE 8

6-(3-Aminophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-1,5-pyrimidinedicarboxylic acid, dimethyl ester

15

The title compound was prepared from the compound of Example 7 according to the method described in Example 2 using AcOH as solvent. A white solid was obtained (97% yield): mp 190-193 °C; ^1H NMR (CDCl_3) δ 7.65 (s, 1 H), 7.05 (t, 1 H, $J = 7.8$ Hz), 6.69 (d, 1 H, $J = 7.8$ Hz), 6.64 (s, 1 H), 6.57 (d, 1 H, $J = 7.8$ Hz), 6.30 (s, 1 H), 3.86 (s, 3 H), 3.74 (s, 3 H), 2.36 (s, 3 H); ^{13}C NMR (CDCl_3) δ 165.6, 153.7, 150.1, 146.6, 145.7, 140.6, 129.6, 116.6, 114.9, 113.0, 105.0, 56.0, 54.3, 51.6, 18.1.

20

Anal. Calcd for $\text{C}_{15}\text{H}_{17}\text{N}_3\text{O}_5 \cdot 0.2 \text{H}_2\text{O}$: C, 55.79; H, 5.43; N, 13.01.

25

Found: C, 56.02; H, 5.53; N, 12.66.

EXAMPLE 9

30

1,2,3,6-Tetrahydro-4-methyl-2-oxo-6-[3-[[[3-(4-phenyl-1-piperidinyl)propyl]amino]carbonyl]amino]phenyl]-1,5-pyrimidinedicarboxylic acid, dimethyl ester

The title compound was prepared from the compound of Example 8 and the intermediate of Formula VII, according to the method described in Example 3. The solvent was removed in vacuo from the reaction mixture, and the residue was partitioned between CH₂Cl₂ and H₂O. The organic extract was dried over Na₂SO₄ and the solvent removed in vacuo. The residue was then subjected to flash chromatography (SiO₂: MeOH/CH₂Cl₂), obtaining a fraction enriched with the desired product. This was dissolved in CH₂Cl₂, then 1N HCl/Et₂O (1.5 mL) was added, and the solvent removed in vacuo. The title compound was isolated by flash chromatography (SiO₂: MeOH/CH₂Cl₂) as a light yellow solid (13% yield): mp 125-130 °C; ¹H NMR (DMSO-*d*₆) δ 10.29 (br s, 1 H), 10.15 (s, 1 H), 8.90 (s, 1 H), 7.40 (d, 1 H, *J* = 8.1 Hz), 7.27 (m, 7 H), 6.73 (d, 1 H, *J* = 7.8 Hz), 6.49 (m, 1 H), 6.13 (s, 1 H), 3.75 (s, 3 H), 3.64 (s, 3 H), 3.52 (m, 2 H), 3.16 (m, 2 H), 3.04 (m, 4 H), 2.79 (m, 1 H), 2.27 (s, 3 H), 2.00 (m, 6 H); ¹³C NMR (DMSO-*d*₆) δ 165.2, 155.4, 153.7, 148.6, 147.8, 144.3, 140.9, 140.2, 128.9, 128.6, 126.6, 118.4, 117.2, 115.4, 103.0, 54.9, 54.0, 52.0, 51.4, 38.8, 36.5, 30.0, 24.7, 17.1.

Anal. Calcd for C₃₀H₃₇N₅O₆ • HCl • 1.3 H₂O: C, 57.79; H, 6.56; N, 11.23. Found: C, 57.89; H, 6.27; N, 11.20.

EXAMPLE 10

1,2,3,6-Tetrahydro-4-methyl-2-oxo-6-[3-[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-1,5-pyrimidinedicarboxylic acid, dimethyl ester

A solution of the compound of Example 8 (1.35 g, 4.23 mmol) and 3-chloropropyl isocyanate (0.5 mL, 5 mmol) in CH₂Cl₂ (50 mL) was refluxed for 3 h. The solvent was removed in vacuo, and the residue was

subjected to flash chromatography (SiO₂: 3% MeOH/CH₂Cl₂) to afford the urea as a pale yellow solid [1.51 g, 82% yield. A mixture of this material (1.3 g, 3.0 mmol), 4-(3-methoxyphenyl) piperidine [prepared by the method of G.A. Loew, *et al.*, Mol. Pharmacol., (1988), 34, 363-376]

5 (600 mg, 3.1 mmol), K₂CO₃ (850 mg), and NaI (80 mg) in MeCN (75 mL) was refluxed overnight. The reaction mixture was then taken up in water and extracted with CH₂Cl₂. The organic extract was dried (Na₂SO₄), and the solvent was removed in vacuo. The residue was then subjected to flash chromatography (SiO₂: 7.5-10% MeOH/CH₂Cl₂) to afford the title

10 compound as a white solid (115 mg, 6% yield): mp 85-90 °C; MS (IS) m/z 594 (MH⁺); ¹H NMR (CDCl₃) δ 7.69 (s, 1 H), 7.45 (d, 1 H, J = 8.7 Hz), 7.19 (m, 3 H), 6.96 (d, 1 H, J = 7.8 Hz), 6.72 (m, 4 H), 6.29 (s, 1 H), 5.83 (m, 1 H), 3.78 (s, 3 H), 3.76 (s, 3 H), 3.70 (s, 3 H), 3.19 (m, 2 H), 3.00 (m, 2 H), 2.40 (m, 3 H), 2.30 (s, 3 H), 2.00 (m, 2 H), 1.76 (m, 2 H), 1.67 (m, 4

15 H); ¹³C NMR (CDCl₃) δ 165.7, 159.6, 156.4, 150.2, 147.7, 146.6, 140.5, 139.9, 129.4, 121.3, 119.8, 119.2, 117.2, 112.9, 111.2, 104.9, 56.2, 56.0, 55.1, 54.2, 54.1, 51.6, 42.4, 38.7, 33.0, 26.9, 17.8.


High Resolution Mass Spectrum Calcd for C₃₁H₄₀N₅O₇ (MH⁺):

20 594.2928. Found: 594.2906.

What is claimed is:

1. A compound of the formula

5



wherein

R is hydrogen, C₁₋₃ alkyl or CO₂R¹;

- 10 R¹ is C₁₋₃ alkyl; and

R² is phenyl or methoxyphenyl;

or a nontoxic pharmaceutically acceptable salt thereof.

2. A compound of claim 1 wherein R is CO₂R¹.

15

3. A compound of claim 2 wherein R¹ is methyl.

4. The compound of claim 1 which is 1,2,3,6-tetrahydro-4-methyl-2-oxo-6-[3-[[[3-(4-phenyl-1-piperidiny)propyl]amino]carbonyl]-

- 20 amino]phenyl]-1,5-pyrimidinedicarboxylic acid, dimethyl ester or a nontoxic pharmaceutically acceptable salt thereof.

5. The compound of claim 1 which is 1,2,3,6-tetrahydro-4-methyl-2-oxo-6-[3-[[[3-[4-(3-methoxyphenyl)-1-piperidiny]propyl]amino]carbonyl]-

- 25 amino]phenyl]-1,5-pyrimidinedicarboxylic acid, dimethyl ester or a nontoxic pharmaceutically acceptable salt thereof.

6. A method of promoting weight loss and treating eating disorders in a mammal which comprises administering to a mammalian host an anorexiant effective dose of a compound claimed in claim 1.
- 5 7. A pharmaceutical composition for use in promoting weight loss and treating eating disorders comprising an anorexiant effective amount of a compound claimed in claim 1 in combination with a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International application No.:

PCT/US98/01429

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07D 401/12; A61K 31/505

US CL :544/316; 514/274

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 544/316; 514/274

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS-ON-LINE Structure Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Chem. Abstr., Vol. 108, No. 17, (Columbus, OH, USA), page 741, column 1, the abstract No. 150408, AKHTAR, M.S. "Syntheses of 2,3-dihydro-SH-thiazolo [3,2-a] pyrimidines and tetrasubstituted dihydropyrimidine derivatives as possible anthelmintic agents", Indian J. Chem., Sect B (1987) 26 B(6), 556-61 (English).	1-7



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

24 APRIL 1998

Date of mailing of the international search report

29 MAY 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOHN M. FORD aco

Telephone No. (703) 308-1235